We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

55 hedge funds and large institutions have $215M invested in ProQR Therapeutics in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

2% less funds holding

Funds holding: 56 → 55 (-1)

4.18% less ownership

Funds ownership: 64.97% → 60.79% (-4.2%)

17% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 18

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

37% less capital invested

Capital invested by funds: $340M → $215M (-$125M)

Holders
55
Holders Change
-1
Holders Change %
-1.79%
% of All Funds
1.19%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
8
Increased
15
Reduced
18
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$5.51M
2
KA
Kerrisdale Advisers
Florida
+$4.74M
3
SFM
Sphera Funds Management
Israel
+$3.3M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.29M
5
ACM
Aquilo Capital Management
California
+$3.09M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$10M
2
O
OrbiMed
New York
-$7.07M
3
NAMA
Nikko Asset Management Americas
New York
-$4.02M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$3.63M
5
Goldman Sachs
Goldman Sachs
New York
-$2.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$34M – – –
RI
2
RTW Investments
New York
$33.9M – – –
Goldman Sachs
3
Goldman Sachs
New York
$30.4M -$2.21M -187,246 -5%
Jennison Associates
4
Jennison Associates
New York
$25.9M -$468K -39,665 -1%
O
5
OrbiMed
New York
$12.6M -$7.07M -599,529 -30%
AG
6
Artal Group
Luxembourg
$11.8M -$1.18M -100,000 -7%
BlackRock
7
BlackRock
New York
$7.32M +$203K +17,234 +2%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$7.08M -$2.12M -180,100 -19%
ACM
9
Aquilo Capital Management
California
$6.82M +$3.09M +262,163 +54%
HSBC Holdings
10
HSBC Holdings
United Kingdom
$4.55M – – –
ClearBridge Investments
11
ClearBridge Investments
New York
$4.47M -$52.1K -4,420 -0.9%
SFM
12
Sphera Funds Management
Israel
$4.28M +$3.3M +280,000 +147%
UBS Group
13
UBS Group
Switzerland
$4.25M +$5.51M +466,785 New
KA
14
Kerrisdale Advisers
Florida
$4.24M +$4.74M +401,900 +631%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$3.13M -$1.41M -119,500 -26%
Millennium Management
16
Millennium Management
New York
$2.9M +$1.59M +134,607 +73%
Wellington Management Group
17
Wellington Management Group
Massachusetts
$2.54M +$3.29M +278,523 New
DCM
18
DAFNA Capital Management
California
$2.38M – – –
Caisse de Depot et Placement du Quebec (CDPQ)
19
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$2.27M – – –
AGA
20
Altrinsic Global Advisors
Connecticut
$1.83M +$27.1K +2,300 +1%
OPPM
21
Opus Point Partners Management
New York
$1.26M – – –
State Street
22
State Street
Massachusetts
$994K -$48.6K -4,118 -4%
AA
23
ALPS Advisors
Colorado
$740K +$960K +81,350 New
Legal & General Group
24
Legal & General Group
United Kingdom
$610K – – –
FSA
25
Franklin Street Advisors
North Carolina
$546K – – –
1
2 3

PRQR Hedge Fund Activity: Q2 2019 in Review

55 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2019, worth a combined $215M — down 37% from $340M a quarter earlier.

Fund positioning in PRQR was balanced in Q2 2019: 8 funds opened new positions, 8 closed out, 15 added to existing stakes and 18 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $5.51M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $10M sold.

  • 55 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2019, down from 56 in Q1 2019.
  • Funds reported $215M of ProQR Therapeutics stock for Q2 2019, down 37% quarter-over-quarter.
  • 8 funds opened new ProQR Therapeutics positions in Q2 2019 and 8 closed out, a net change of 0 holders.
  • The largest ProQR Therapeutics buyer in Q2 2019 was UBS Group, an estimated $5.51M added.
  • The largest ProQR Therapeutics seller in Q2 2019 was Perceptive Advisors, an estimated $10M sold.

Based on aggregated 13F filings for Q2 2019.